mRNA-based – Page 5 – Communicable Diseases Research

SARS-CoV-2 variants with reduced infectivity and varied sensitivity to the BNT162b2 vaccine are developed during the course of infection

감염성이 감소하고 BNT162B2 백신에 대한 감도가 다양한 SARS-COV-2 변이체가 감염 과정에서 개발됩니다.

Clinical Trial

Published on 2022-01-122022-08-13
Journal: PLoS Pathogens [Category] Biochemistry, 변종, 임상, 치료기술, 치료법,

Effect of mRNA Delivery Modality and Formulation on Cutaneous mRNA Distribution and Downstream eGFP Expression

Article

Published on 2022-01-082022-10-28
Journal: Pharmaceutics [Category] COVID-19,

Six-Month Follow-Up after Vaccination with BNT162b2: SARS-CoV-2 Antigen-Specific Cellular and Humoral Immune Responses in Hemodialysis Patients and Kidney Transplant Recipients

Article

Published on 2022-01-052022-10-28
Journal: Pathogens [Category] COVID-19,

Analysis of Neutralization Titers against SARS-CoV-2 in Health-Care Workers Vaccinated with Prime-Boost mRNA–mRNA or Vector–mRNA COVID-19 Vaccines

Article

Published on 2022-01-042022-10-28
Journal: Vaccines [Category] COVID-19,

Liver injury after mRNA-based SARS-CoV-2 vaccination in a liver transplant recipient

간 이식 환자에서 mRNA 기반 SARS-CoV-2 백신 접종 후 간 손상

Article

Published on 2022-01-012022-09-12
Journal: Clinics and research in hepatology and gastroenter [Category] MERS, SARS, 진단,

[키워드] Abstract COVID-19 Injury liver Liver transplantation mRNA-based SARS-CoV-2 vaccination Toxicity Vaccine
[DOI] 10.1016/j.clinre.2021.101743 PMC 바로가기 [Article Type] Article

Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment

Research Report

Published on 2021-12-232022-10-31
Journal: Cancer immunology, immunotherapy : CII [Category] COVID-19,

[키워드] Adverse adverse event adverse events AEs antibody approved Cancer cancer patient Cancer patients clinical cohort study combination treatment coronavirus disease COVID-19 COVID-19 vaccination COVID-19 vaccine dose eight event fatigue first vaccination FIVE follow-up time Frequency Germany grade 3 Immune-checkpoint inhibitors Immunotherapy information inhibitor injection investigated Ipilimumab irAE median Melanoma men Mild moderate pain mRNA-based nivolumab Patient patients patients’ medical records Precaution receiving reported retrieved Safe Seven Side effect Side effects supplementary material the timing therapy treated Treatment vaccination Vaccine was used
[DOI] 10.1007/s00262-021-03133-w PMC 바로가기 [Article Type] Research Report

Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients A Randomized Clinical Trial

신장 이식 수용자에서 상 동성 대 이종 제 3 백신 용량 4 주 후 SARS-COV-2 항체 반응의 비교 무작위 임상 시험

Randomized Controlled Trial

Published on 2021-12-202022-08-13
Journal: JAMA Internal Medicine [Category] Fulltext, MERS, 임상, 진단,

[키워드] 1:1 95% CI addition age Analysis antibody Antibody Response antibody response rate association BNT162b2 Characteristics clinical clinical trial comparable conducted develop dose doubling Effectiveness end point EudraCT evaluated finding Frequency groups Heterologous homologous immune response immunogenicity Immunosuppression Importance induce injection injection site interferon interferon-γ kidney transplant kidney transplant recipient kidney transplant recipients local pain Logistic regression measure mRNA mRNA vaccine mRNA-1273 mRNA-based Neutralizing antibodies neutralizing antibody no statistically significant difference objective Odds ratio participant Patient performed plasma Point positive response Preliminary data randomized clinical trial reactogenicity recipient Registration Relevance response response rate Result Safe SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 antibody SARS-CoV-2 spike protein SARS-CoV-2 vaccination SARS-CoV-2 vaccine secondary Seroconversion seroconverted patient seroconverted patients setting significantly single center Spike protein statistically significant difference study population systemic symptom systemic symptoms T-cell Response the SARS-CoV-2 the vaccine the vaccines Transplant vaccination Vaccination strategy Vaccine vaccine dose vaccine response Vaccines vector Vector-based vaccine Viral Viral vector vaccines virus Week women
[DOI] 10.1001/jamainternmed.2021.7372 PMC 바로가기 [Article Type] Randomized Controlled Trial

Differential Effect of SARS-CoV-2 Spike Glycoprotein 1 on Human Bronchial and Alveolar Lung Mucosa Models: Implications for Pathogenicity

Article

Published on 2021-12-172022-10-28
Journal: Viruses [Category] COVID-19, SARS,

[키워드] ACE2 air–liquid interface Alpha Altered alveolar Analysis anti-viral response bronchial bronchial epithelial cell canonical cell membrane coronavirus COVID-19 COVID-19 vaccines cytokine differentially regulated gene Effect enzyme exposure to expression fibrosis host cell receptor Human IFN IFNγ IL10 IL12 IL13 IL2 IL4 IL6 IL8 Infection Influenza integrin interferon Ligand lung Lung fibrosis MERS (middle east respiratory syndrome) mRNA-based mucosa Mutation Necrosis neutralizing antibody p53 pathogenicity pathway platform pro-fibrotic pro-inflammatory cytokine pulmonary receptor Receptor binding domain Recombinant S1 protein regions robust S1 protein S1 subunit SARS (severe acute respiratory syndrome) SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 variant secreted Signaling significantly spike spike glycoprotein Spike protein the S1 subunit TLR TLR4 Type II pneumocyte virus
[DOI] 10.3390/v13122537 PMC 바로가기 [Article Type] Article

A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses

Article

Published on 2021-12-162022-10-28
Journal: Vaccines [Category] COVID-19,

First diagnosis of thrombotic thrombocytopenic purpura after SARS-CoV-2 vaccine – case report

Case Report

Published on 2021-12-112022-10-28
Journal: BMC Nephrology [Category] COVID-19, SARS,

[키워드] Acute kidney injury addition Admission alteration antibody Case report Corticosteroid COVID-19 vaccines described Diagnosis diagnostic differential diagnosis disintegrin dose excluded Fever Final first dose first symptom headache Hematuria Hemolysis hemolytic anemia immune initial initiated malaise male Mild Moderna motif mRNA-1273 mRNA-based nausea neurological normalized pathophysiological Patient petechial bleeding plasma exchange Platelet purpura receive receiving reported resolved SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine Symptom the patient therapy thrombocyte thrombocytopenia thrombotic Thrombotic thrombocytopenic Thrombotic thrombocytopenic purpura USA vaccination Vaccine Vaccines vomiting while
[DOI] 10.1186/s12882-021-02616-3 PMC 바로가기 [Article Type] Case Report